The Patent Finder

Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies

Dyne Therapeutics, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 13 of these applications claim priority to application 63/220,262, filed Jul 9, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 12,629,426Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
 · Medium confidence
UsedRemaining
Dyne Therapeutics, Inc.In forceMedium confidence
US 11,633,498Muscle Targeting Complexes and Uses Thereof for Treating Myotonic Dystrophy
In force
 · High confidence
Dyne Therapeutics, Inc.In forceHigh confidence
US 11,638,761Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
In force
 · High confidence
Dyne Therapeutics, Inc.In forceHigh confidence
US 11,672,872Anti-Transferrin Receptor Antibody and Uses Thereof
In force
 · High confidence
Dyne Therapeutics, Inc.In forceHigh confidence
US 11,679,161Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
In force
 · Medium confidence
Dyne Therapeutics, Inc.In forceMedium confidence
US 11,759,525Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
In force
 · Medium confidence
Dyne Therapeutics, Inc.In forceMedium confidence
US 11,771,776Muscle Targeting Complexes and Uses Thereof for Treating Dystrophinopathies
In force
 · Medium confidence
Dyne Therapeutics, Inc.In forceMedium confidence
US 11,839,660Anti-Transferrin Receptor Antibody and Uses Thereof
In force
 · High confidence
Dyne Therapeutics, Inc.In forceHigh confidence
US 11,844,843Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
In force
 · Medium confidence
Dyne Therapeutics, Inc.In forceMedium confidence
US 11,969,475Muscle Targeting Complexes and Uses Thereof for Treating Facioscapulohumeral Muscular Dystrophy
In force
 · Medium confidence
Dyne Therapeutics, Inc.In forceMedium confidence
18 more records in this group · Pro
10 of 28 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 28.
Upgrade to Pro
23 of these are in force and held by Dyne Therapeutics, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited